astragaloside a has been researched along with Pulmonary Arterial Remodeling in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, A; Li, C; Li, G; Li, S; Meng, F; Wu, S; Zha, J; Zhang, S; Zhu, H; Zhu, L | 1 |
| Guo, L; Jiao, Y; Jin, H; Kim, SC; Li, X; Liu, J; Ma, Y; Shen, L; Zhao, R; Zhou, Z | 1 |
| Dai, RZ; Gao, F; Li, JS; Zhang, DQ; Zhang, YM | 1 |
3 other study(ies) available for astragaloside a and Pulmonary Arterial Remodeling
| Article | Year |
|---|---|
Astragaloside IV ameliorates pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension by restraining the T follicular helper cell response and expanding T follicular regulatory cell response.
Topics: Animals; Hypertension, Pulmonary; Hypoxia; Mice; Pulmonary Artery; Quality of Life; Saponins; Sildenafil Citrate; T Follicular Helper Cells; Triterpenes; Vascular Remodeling | 2022 |
Astragaloside IV blocks monocrotaline‑induced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling.
Topics: Animals; Hypertension, Pulmonary; Inflammation; Male; Monocrotaline; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Saponins; Triterpenes; Vascular Remodeling | 2021 |
Astragaloside IV inhibits Angiotensin II-stimulated proliferation of rat vascular smooth muscle cells via the regulation of CDK2 activity.
Topics: Angiotensin II; Animals; Atherosclerosis; Cell Line; Cyclin-Dependent Kinase 2; G1 Phase; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Rats; S Phase; Saponins; Triterpenes; Vascular Remodeling | 2018 |